RBC Capital Markets adjusted its price target for Amgen (NASDAQ:AMGN) shares, reducing it slightly from $324 to $320, while retaining an Outperform rating on the biotechnology firm's stock. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback